To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Relapsed/Refractory Lymphoma Clinical Trial

Official title:
Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Relapsed or Refractory Lymphoma

Status Recruiting

Clinical Trial Summary

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05400876
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Tongyu Lin, Doctor
Phone	18108243837
Email	tongyulin@hotmail.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	June 9, 2022
Completion date	October 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02259010` - A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma	Phase 1
Not yet recruiting	`NCT05293028` - Study of F527 in Patients With Relapsed or Refractory Lymphoma	Phase 1
Recruiting	`NCT05713110` - A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma	Phase 2
Recruiting	`NCT05189093` - Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma	Phase 1/Phase 2
Terminated	`NCT05271279` - A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors	Early Phase 1
Completed	`NCT02214147` - Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function	Phase 1